Labiana Health S.A. (LAB.MC) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Spain · ISIN ES0105638003

Price
5.40 EUR
Market cap
45.84 m EUR
P/E (2025)
15.06
P/S (2025)
0.61
Dividend yield
0.00 %
Net margin
3.42 %
Return on equity (ROE)
50.54 %
Return on assets (ROA)
4.46 %

Labiana Health S.A. financials

Fiscal year20242025
Revenue66.26 m EUR75.18 m EUR
Gross profit40.94 m EUR45.97 m EUR
Operating income5.10 m EUR7.30 m EUR
EBIT4.81 m EUR7.11 m EUR
Net income253,449.61 EUR2.57 m EUR
Diluted EPS – continuing operations0.04 EUR0.36 EUR

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Labiana Health S.A.

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, the company offers contract developments, quality system and manufacturing services. Labiana Health S.A. was founded in 1958 and is based in Pozuelo de Alarcón, Spain.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.